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COMMENT&RESPONSE
Observations on a 2-Step Approach to Screening
for ParkinsonDisease
To the Editor We read with interest the report from Jennings
et al.1 The study showed that, amonghyposmic individuals, a
dopamine transporter (DAT)deficit atbaseline identified those
with a high relative risk of conversion to clinical Parkinson
disease (PD) after 4 years of follow-up.1
Powercalculations for randomizedclinical trialsofdisease-
modifying therapy in prodromal PD suggest that sample sizes
will need to include hundreds to thousands of participants to
achievesufficient statisticalpower.2Using thenumbersateach
stage from this study and a previous Parkinson’s Associated
Risk Study (PARS) report, we observed that 9400 partici-
pants were sent a $30 smell test (including postage), which
wouldhavecost approximately $280000.Among these, there
were around 200participantswith hyposmiawho consented
to have a DaTscan (approximately $1000 for the tracer and
single-photon emission computed tomography scan), which
wouldhavecost approximately$200000.Thisapproach iden-
tifiedaround20participants thathadhyposmiaandaDATdefi-
cit. Thismeans that identifying a sufficient number of partici-
pantswithhyposmia andaDATdeficit, topower a clinical trial
with 500 participants in each arm and incident PD as the
outcome, would cost approximately $24 million.
Thesecosts,while substantial,maybe justifiable ifdisease-
modifying therapy were shown to delay conversion to clini-
cal PD and progression to advanced PD. However, the lack of
information on incident PD in participants who were not
hyposmic and/or underwent scanning means that only the
effect of a DAT deficit in those with hyposmia can be evalu-
ated, and not the strengths of the 2-step process.
An interesting finding was the presence of subtle motor
dysfunctionatbaseline in thosewithaDATdeficit.Wetoohave
observed subtle motor dysfunction among at-risk partici-
pants in the PREDICT-PD study.3 Given the lack of association
with hyposmia at baseline,4 subtle motor dysfunction may
be an important, independent predictor of thosewhogoon to
develop clinically defined PD.
We agree that the PARS approach probably identifies
Parkinson disease, as opposed to other atypical parkinso-
nian syndromes or Parkinson-dementia syndromes, and
that DAT single-photon emission computed tomography
will play an important role as an imaging marker of the pro-
dromes of PD. Perhaps exploring the role of DAT single-
photon emission computed tomography as a progression
marker for randomized clinical trials among those estimated
to be at high risk (which the authors allude to), rather than
as a predictive marker, would maximize benefit and use.
There is also a strong argument for an additional low-cost
screening step before smell testing, along with an assess-
ment of subtle motor dysfunction, to enrich and engage
participants from the outset.
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